How long before arterial stiffness changes?

The trial that showed benefit ran for three years. Shorter studies move the K status biomarker but not the stiffness measurement.

Is MK-7 better than MK-4 or K1?

For vascular endpoints, yes. MK-7 has a much longer half-life and reaches tissue outside the liver, which K1 largely does not.

Can I take it if I am on warfarin?

No, not without your prescriber's explicit direction. K2 opposes the drug and destabilises INR.

Outcome

Moderate Evidence

Vitamin K2 for Arterial Flexibility

Vitamin K2 activates matrix Gla protein, the body's main inhibitor of vascular calcification, with long-term trial support for reduced arterial stiffness.

Overview

Arterial flexibility describes how readily the large elastic arteries expand and recoil with each heartbeat. It is measured as pulse wave velocity or as a stiffness index, and it deteriorates with age, hypertension and vascular calcification. Vitamin K2 enters this picture through a single specific job: activating matrix Gla protein, the body's main local inhibitor of calcium deposition in the arterial wall.

The strongest human signal comes from a three-year trial in healthy postmenopausal women, where 180 mcg of MK-7 daily reduced carotid stiffness and pulse wave velocity, with the largest effect in women who started with the stiffest arteries. That is a meaningful result, but it is one population over one long duration. Trials in higher-risk groups have been less encouraging. In people with type 2 diabetes and chronic kidney disease, vitamin K clearly improved K status yet did not slow femoral or coronary calcification. The honest reading is that K2 may help preserve elasticity before heavy calcification sets in, and is unlikely to reverse it once established.

Verdict

Likely effective

One long-duration RCT shows real improvement in arterial stiffness in postmenopausal women; a trial in advanced kidney disease and diabetes found no effect on calcification. Benefit appears population-dependent.

How It Works

Matrix Gla protein is produced in the vascular wall in an inactive form and must be carboxylated by a vitamin K-dependent enzyme before it can bind calcium and keep it out of elastic fibres. When K status is low, uncarboxylated matrix Gla protein accumulates, and higher circulating levels of that inactive form track with stiffer arteries and worse cardiovascular outcomes.

Menaquinone-7 is the form used in most successful trials because its long half-life keeps extra-hepatic tissues, including the arterial wall, supplied between doses. Vitamin K1 is cleared quickly by the liver and largely spent on clotting factors, which is one reason dietary K1 intake does not reliably move vascular endpoints. This mechanism is preventive rather than restorative. K2 reduces new mineral deposition in elastic tissue; it does not dissolve calcium already embedded in a plaque, which explains why late-stage calcification trials come back null.

Target protein: Matrix Gla protein in the vascular wall
Biomarker: Dephosphorylated uncarboxylated matrix Gla protein (dp-ucMGP)
Preferred form: Menaquinone-7 (MK-7), long half-life
Mode of action: Prevents new calcium deposition rather than reversing it
Endpoint moved: Carotid stiffness index and pulse wave velocity

Dosing & Protocol

The dose that produced the arterial stiffness result was 180 mcg of MK-7 daily for three years. Shorter courses lower dp-ucMGP within weeks, but no trial has shown a change in stiffness in under about two years, so this is a long-horizon intervention rather than something you evaluate over a season.

Context	Dose	Form	Timing
Trial dose for arterial stiffness	180 mcg daily	MK-7 (menaquinone-7)	With a fat-containing meal
General K status support	90-180 mcg daily	MK-7	Any meal with fat
Combined with vitamin D	100-200 mcg daily	MK-7 alongside D3	Same meal
Minimum useful duration	24-36 months	MK-7	Daily, uninterrupted

1
Confirm you are not on warfarin· Before starting
Vitamin K antagonists and K2 supplementation are directly opposed. This is a hard stop, not a caution.
2
Take 180 mcg MK-7 with fat· Daily
Vitamin K is fat-soluble; absorption from a fat-free dose is poor.
3
Keep vitamin D and calcium sensible· Ongoing
K2 is most often used alongside vitamin D. Do not push calcium supplements higher on the assumption K2 will redirect it.
4
Reassess at 24 months· Month 24
Pulse wave velocity or carotid stiffness measurement is the only meaningful check. Symptoms tell you nothing here.

Do not expect a felt effect

Arterial flexibility is a measured endpoint with no symptoms attached. If you are not willing to measure it, you will have no way to know whether three years of supplementation did anything.

Evidence

Two randomised trials anchor this pairing and they point in different directions, which is precisely why the verdict stops short of strong. Both are listed below with their populations, because population is the variable that appears to decide the result.

Randomised trials linked to this pairing.

Vitamin K supplementation and vascular calcification in people with type 2 diabetes and chronic kidney disease: a randomized controlled trial

Score: 8/10

2019

rct

n=68

Zwakenberg SR, de Jong PA, Bartstra JW +3 more

Six months of MK-7 did not reduce femoral or coronary artery calcification despite improved vitamin K status.

View source

Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial

Score: 8/10

2015

rct

n=244

Knapen MH, Braam LA, Drummen NE +3 more

Carotid artery stiffness and pulse wave velocity decreased significantly after three years of MK-7.

View source

Best available evidence: Three-year double-blind RCT in 244 healthy postmenopausal women
Typical effect: Significant reduction in carotid stiffness index and pulse wave velocity
Studied dose: 180 mcg MK-7 daily
Time to effect: Measurable at three years; not at shorter durations
Main limitation: No benefit on calcification in diabetes with chronic kidney disease

Safety

MK-7 has an unusually clean safety record at supplemental doses, with no established upper limit and no consistent adverse event signal in multi-year trials. The single serious issue is pharmacological rather than toxicological: it directly antagonises warfarin and related anticoagulants.

What to watch

Contraindicated with warfarin and other vitamin K antagonists

Occasional mild gastrointestinal upset

Unstudied in pregnancy at supplemental doses

No benefit demonstrated in advanced kidney disease

Not a substitute for blood pressure control

Interactions & Conflicts

Most K2 interactions are about competing with, or being made redundant by, other therapies rather than causing harm directly. The anticoagulant interaction is the exception and it is absolute.

Interacts with	Severity	Mechanism	Action
Warfarin / acenocoumarol	high	K2 directly reverses vitamin K antagonism and destabilises INR	Do not supplement unless your prescriber directs and monitors it
Vitamin D3 (high dose)	low	Increases calcium absorption; K2 is often paired to direct it	Reasonable combination; keep D within normal replacement doses
Calcium supplements	moderate	High supplemental calcium is associated with vascular calcification	Prioritise dietary calcium rather than raising supplement doses
Orlistat and bile acid sequestrants	moderate	Reduced absorption of fat-soluble vitamins	Separate dosing by several hours

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.